Related Experiment Video

Updated: Jun 20, 2026

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment
06:48

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment

Published on: April 29, 2022

Association of gene polymorphisms with chronic kidney disease in Japanese individuals

Tetsuro Yoshida1, Kimihiko Kato, Kiyoshi Yokoi

  • 1Department of Cardiovascular Medicine, Inabe General Hospital, Inabe, Japan.

International Journal of Molecular Medicine
|September 3, 2009
PubMed

Insights

Genetic variants in six genes, including F10, are linked to chronic kidney disease (CKD) prevalence in Japanese individuals. The F10 (rs5962) polymorphism showed the strongest association, aiding in genetic risk assessment for CKD.

Area of Science:

  • Genetics
  • Nephrology
  • Epidemiology

Background:

  • Chronic kidney disease (CKD) is a significant risk factor for end-stage renal disease and cardiovascular disease.
  • Early detection and intervention are crucial for preventing CKD complications.
  • Genetic factors contributing to CKD susceptibility remain largely unidentified.

Purpose of the Study:

  • To identify genetic variants associated with CKD susceptibility in a Japanese population.
  • To investigate the role of specific gene polymorphisms in CKD prevalence.

Main Methods:

  • A case-control study involving 4,829 Japanese individuals (757 CKD patients, 4,072 controls).
  • Genotyping of 40 polymorphisms across 39 candidate genes.
  • Statistical analyses including chi-square tests and multivariable logistic regression.

Main Results:

  • Six polymorphisms in F10, PITRM1, PCSK2, JPH3, MYO7B, and AKAP12 were significantly associated with CKD prevalence (P<0.05).
  • The F10 (rs5962) C>T polymorphism exhibited the strongest association with CKD.
  • Estimated glomerular filtration rate (eGFR) was used to define CKD status.

Conclusions:

  • Specific genetic polymorphisms, particularly in F10, are associated with CKD risk in Japanese individuals.
  • Genotyping F10 (rs5962) may assist in evaluating genetic predisposition to CKD.
  • Further research is warranted to elucidate the mechanisms underlying these genetic associations.

More Related Videos

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...